AnaptysBio, Inc.
ANABHealthcareNASDAQBiotechnology · Last scanned Jul 18, 2026
Scan Results
Daily timeframePart of the healthcare sector, AnaptysBio, Inc. (ANAB) is listed under Biotechnology. At a $1.72B market cap, AnaptysBio, Inc. ranks as a small-cap company within healthcare. The company's products include Rosnilimab, a selective pathogenic T cell deplete which completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis; ANB033, a CD122 antagonist, which is in a Phase 1b trial for celiac disease and eosinophilic esophagitis; ANB101, a BDCA2 modulator antibody which is in Phase 1a trial that specifically targets plasmacytoid dendritic cells and inhibits interferon secretion and modulates antigen presentation; dostarlimab, a PD-1 antagonist for various solid tumor indications; and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.
Market Cap
$1.72B
Beta
0.38
P/E (TTM)
—
P/E (Fwd)
11.08
EPS (TTM)
$-1.09
EPS (Fwd)
$5.24
ROE
-114.5%
ROA
6.8%
Cash
$286.5M
Total Debt
$277.4M
Free CF
$8.3M
52W Change
235.7%
Annual Financials
Cash vs Debt
With $286.5M in cash and $277.4M in debt, ANAB maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow comes in at $8.3M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. ROE of -114.5% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. An ROA of 6.8% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $63.2M (2021) to $234.6M (2025), reflecting a 271% increase over the period.
The relatively low beta of 0.38 suggests ANAB is a less volatile holding compared to the broader index. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence AnaptysBio, Inc.'s trajectory.